Summary
Prolira, a high-tech SME, has formed a consortium with European academic hospitals (in NL, B, G) and with Key Opinion Leaders who together are revolutionizing delirium care. This is necessary as delirium has severe consequences for patients (death, dementia, slower recovery), hospitals (organizational, time, costs), and society (costs ≈€173 billion).
Every year, at least 3 million Europeans are affected by acute brain failure (delirium), especially hospitalized elderly and patients in ICU. And, the size of this problem will grow with our aging society. Delirium is an acute failure of the brain. Each day of delirium increases the risk of dementia or dying.
Prolira has created a new vital sign monitor based on portable electroencephalography (EEG) technology: DeltaScan. Nurses can use it during bedside checks to scan brain activity for delirium. This simple step is as important as measuring blood pressure. Currently, nurses are only equipped with subjective checklists to detect delirium, leaving the majority of cases undetected, and untreated. With DeltaScan, delirium is detected more often and earlier, benefiting patients, hospitals, and society.
Our medical consortium partners wish to implement DeltaScan into routine care, evaluating the effects and capturing the benefits. It is priceless to get financial support for this clinical testing, which is an absolute requirement for market acceptance. It is a straight road to becoming the Gold Standard in delirium detection and being included in clinical guidelines.
EU H2020 FTI funding will allow us to quantify the concrete benefits of improved delirium care, allowing us access to the marketplace and allowing us to benefit society as soon as possible. As well, this funding will allow our international consortium to be well organized and ready for full-scale scale market launch. Prolira will grow substantially in the years directly after the project, creating meaningful jobs for hundreds of EU citizens.
Every year, at least 3 million Europeans are affected by acute brain failure (delirium), especially hospitalized elderly and patients in ICU. And, the size of this problem will grow with our aging society. Delirium is an acute failure of the brain. Each day of delirium increases the risk of dementia or dying.
Prolira has created a new vital sign monitor based on portable electroencephalography (EEG) technology: DeltaScan. Nurses can use it during bedside checks to scan brain activity for delirium. This simple step is as important as measuring blood pressure. Currently, nurses are only equipped with subjective checklists to detect delirium, leaving the majority of cases undetected, and untreated. With DeltaScan, delirium is detected more often and earlier, benefiting patients, hospitals, and society.
Our medical consortium partners wish to implement DeltaScan into routine care, evaluating the effects and capturing the benefits. It is priceless to get financial support for this clinical testing, which is an absolute requirement for market acceptance. It is a straight road to becoming the Gold Standard in delirium detection and being included in clinical guidelines.
EU H2020 FTI funding will allow us to quantify the concrete benefits of improved delirium care, allowing us access to the marketplace and allowing us to benefit society as soon as possible. As well, this funding will allow our international consortium to be well organized and ready for full-scale scale market launch. Prolira will grow substantially in the years directly after the project, creating meaningful jobs for hundreds of EU citizens.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/820555 |
| Start date: | 01-07-2018 |
| End date: | 30-06-2021 |
| Total budget - Public funding: | 4 484 637,00 Euro - 2 994 425,00 Euro |
Cordis data
Original description
Prolira, a high-tech SME, has formed a consortium with European academic hospitals (in NL, B, G) and with Key Opinion Leaders who together are revolutionizing delirium care. This is necessary as delirium has severe consequences for patients (death, dementia, slower recovery), hospitals (organizational, time, costs), and society (costs ≈€173 billion).Every year, at least 3 million Europeans are affected by acute brain failure (delirium), especially hospitalized elderly and patients in ICU. And, the size of this problem will grow with our aging society. Delirium is an acute failure of the brain. Each day of delirium increases the risk of dementia or dying.
Prolira has created a new vital sign monitor based on portable electroencephalography (EEG) technology: DeltaScan. Nurses can use it during bedside checks to scan brain activity for delirium. This simple step is as important as measuring blood pressure. Currently, nurses are only equipped with subjective checklists to detect delirium, leaving the majority of cases undetected, and untreated. With DeltaScan, delirium is detected more often and earlier, benefiting patients, hospitals, and society.
Our medical consortium partners wish to implement DeltaScan into routine care, evaluating the effects and capturing the benefits. It is priceless to get financial support for this clinical testing, which is an absolute requirement for market acceptance. It is a straight road to becoming the Gold Standard in delirium detection and being included in clinical guidelines.
EU H2020 FTI funding will allow us to quantify the concrete benefits of improved delirium care, allowing us access to the marketplace and allowing us to benefit society as soon as possible. As well, this funding will allow our international consortium to be well organized and ready for full-scale scale market launch. Prolira will grow substantially in the years directly after the project, creating meaningful jobs for hundreds of EU citizens.
Status
CLOSEDCall topic
EIC-FTI-2018-2020Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
